After Hours Summary: LPCN +38% on positive trial results... RS -7% and CMG -2% following guidanceAfter Hours Gainers:
Companies trading higher in after hours in reaction to news: LPCN +38.1% (announces LPCN 1021 achieved primary endpoints confirming the efficacy of twice daily oral administration andgenerally met the pre-specified per dose secondary endpoints for twice daily oral administration), ENPH +14.4% (Enphase Energy enters into a Master License Agreement with Flextronics Industrial), BLCM +6%, DDD +2.1%, CFMS +0.9% (continued strength), EYEG +3.9% (indicated higher after Armistice Capital discloses 9.9% passive stake), ALXN +1.6% (CEO disclosed the purchase of 10K shares at avg price of $116.72/share), TSLA +1.3% (reports nearing deal for China production plant), MU +0.6% (after seeing afternoon strength)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: RS -6.6% (light volume), CMG -2.2%, (reaffirms/clarifies guidance for certain financial and operating results for Q2/FY17),
Companies trading lower in after hours in reaction to news: NEOS -7.3% (continued weakness), AVXS -4.3% (to offer up to $200 million of shares of its common stock in an underwritten public offering), FDUS -2.6% (commences public offering of 1.5 mln shares of its common stock), CLVS -1.7% (commences underwritten public offering of shares of its common stock to raise aggregate proceeds of ~$250 mln), TDOC -0.8% (confirms definitive agreement to acquire Best Doctors; Teladoc reiterates its previously communicated second quarter 2017)
In reaction to strong earnings/guidance: N/A
M&A news:
- NVDQ +92% (to be acquired by Stryker (SYK) for $11.75/share)
- RICE +28% (Rice Energy and EQT (EQT) acquisition confirmed for total consideration of approximately $6.7 billion)
- FNSR +1.5%, AMD +1.4%, MU +1.3%, MOMO +1.3%, NFLX +1.1%, NVDA+1%, AMZN +0.9%, FB +0.9%, MSFT +0.8%, TSLA +0.8%
- CLVS +44% (reports data from Phase 3 ARIEL3 study achieved primary endpoint; plans to submit NDA in next 4 months)
- RIGL +13.2% (FDA has accepted the New Drug Application for TAVALISSE)
- WKHS +4.7% (unveiled its Surefly helicopter concept at the Paris Air Show (Static display B10) and released specifications. The company is now accepting pre-orders for SureFly)
- JD +3.5% (issued an update on its Anniversary Sales)
- HII +3.2% (confirms it has been awarded a $3 billion contract for the detail design and construction of the amphibious assault ship Bougainville)
- VRX +3.2% (announces that its Board has elected John Paulson to serve as a director, effective June 14)
- ADMP +2.9% (continued strength following last week's move higher)
- AAOI +2.9% (continued strength)
- JUNO +2% (presents data from the TRANSCEND trial of JCAR017 in relapsed and refractory aggressive B cell non-Hodgkin lymphoma)
- HZNP +2% (Health Canada has issued a Notice of Compliance for PROCYSBI)
- CRAY +1.9% (receives contract from New Zealand's National Institute of Water and Atmospheric Research worth $18 mln)
- CS +3.7% (upgraded to Buy from Hold at Deutsche Bank )
- AKS +2.8% (upgraded to Buy from Neutral at Longbow)
- X +2.3% (upgraded to Buy from Neutral at Longbow)
- NUE +1.1% (upgraded to Buy from Neutral at Longbow)
- AAPL +1.1% (target raised to $180 at Maxim Group)
- BIIB +1.1% (upgraded to Neutral from Sell at UBS)
- AGCO +1% (upgraded to Neutral from Underperform at BofA/Merrill)
- CNHI +0.9% (upgraded to Buy from Neutral at BofA/Merrill)
In reaction to disappointing earnings/guidance:
- N/A
- EQT -5.4% (Rice Energy (RICE) and EQT acquisition confirmed for total consideration of ~$6.7 billion)
- SGEN -11.7% (discontinuing the phase 3 CASCADE clinical trial of vadastuximab talirine)
- TSRO -11.3% (after CLVS reported positive topline data from the confirmatory phase 3 ARIEL3 trial of rucaparib; PARP competitor Tesaro trading lower in response)
- LTBR -3.2% (files for 1,853,960 share common stock offering by Aspire Capital Fund)
- PI -3.1% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- TRIP -2.1% (downgraded to Underperform from Neutral at Credit Suisse)
- LYV -1.3% (downgraded to Neutral from Buy at Northcoast)
- IHG -1.3% (downgraded to Neutral from Outperform at Credit Suisse)